Pharmacology and clinical use of voriconazole
- PMID: 19947892
- DOI: 10.1517/17425250903463878
Pharmacology and clinical use of voriconazole
Abstract
Importance of the field: Voriconazole is an extended-spectrum triazole developed specifically to target Aspergillus spp. and is now indicated as primary therapy in this circumstance. However, it has a broad spectrum of activity against both yeasts and molds and is also a viable treatment option in the treatment of other mycoses.
Areas covered in this review: This review discusses the mechanism of action, the pharmacodynamics and pharmacokinetics and the most common mechanisms of resistance to this agent. An overview of therapeutic drug monitoring, drug-drug interactions and pivotal trials are also reviewed.
What the reader will gain: The reader will gain further knowledge of the unique aspects of voriconazole compared to other currently available antifungal agents.
Take home message: Voriconazole offers distinct advantages over several other antifungals. The side effect profile of voriconazole is unique compared to other triazole agents. Concern for drug-drug interactions due to a frequently shared common metabolic pathway has prompted heightened interest in the use of therapeutic drug monitoring for concerns of toxicity, drug-drug interactions and in attempts to ensure efficacy. These aspects as well as a review of important clinical information pertaining to voriconazole are discussed here.
Similar articles
-
New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Expert Rev Anti Infect Ther. 2009 Oct;7(8):981-98. doi: 10.1586/eri.09.67. Expert Rev Anti Infect Ther. 2009. PMID: 19803707 Review.
-
Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.Expert Rev Hematol. 2009 Jun;2(3):237-54. doi: 10.1586/ehm.09.13. Expert Rev Hematol. 2009. PMID: 21082966 Review.
-
Therapeutic drug monitoring of voriconazole.Ther Drug Monit. 2008 Aug;30(4):403-11. doi: 10.1097/FTD.0b013e31817b1a95. Ther Drug Monit. 2008. PMID: 18641555 Review.
-
Voriconazole: a new triazole antifungal agent.Clin Infect Dis. 2003 Mar 1;36(5):630-7. doi: 10.1086/367933. Epub 2003 Feb 10. Clin Infect Dis. 2003. PMID: 12594645 Review.
-
Voriconazole. UK 109496.Drugs R D. 1999 Feb;1(2):187-8. doi: 10.2165/00126839-199901020-00020. Drugs R D. 1999. PMID: 10566023 No abstract available.
Cited by
-
Invasive fungal infection of the central nervous system in a patient with acute myeloid leukaemia.Pol J Radiol. 2012 Jan;77(1):54-7. doi: 10.12659/pjr.882582. Pol J Radiol. 2012. PMID: 22802867 Free PMC article.
-
Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy.Infect Drug Resist. 2016 Sep 20;9:229-238. doi: 10.2147/IDR.S63621. eCollection 2016. Infect Drug Resist. 2016. PMID: 27703383 Free PMC article. Review.
-
Anti-fungal therapy: An overview for maxillofacial surgeons in post-covid-19 fungal infections.Natl J Maxillofac Surg. 2022 Sep-Dec;13(3):330-336. doi: 10.4103/njms.njms_412_21. Epub 2022 Dec 10. Natl J Maxillofac Surg. 2022. PMID: 36683940 Free PMC article. Review.
-
Examination of Fluconazole-Induced Alopecia in an Animal Model and Human Cohort.Antimicrob Agents Chemother. 2019 Jan 29;63(2):e01384-18. doi: 10.1128/AAC.01384-18. Print 2019 Feb. Antimicrob Agents Chemother. 2019. PMID: 30455235 Free PMC article.
-
Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate.Antimicrob Agents Chemother. 2013 Jun;57(6):2878-81. doi: 10.1128/AAC.00068-13. Epub 2013 Apr 9. Antimicrob Agents Chemother. 2013. PMID: 23571545 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous